Abbott Laboratories
Abbott Laboratories price
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Stock ticker
- ABT
- Company
- Abbott Laboratories
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- 23995000
- Launch date
- 17 Mar 1980
- Listed exchange
- NYSE
Financials
Summary: ABT reported Revenue of 12.59B (+13.02%), beating expectations; EPS of 1.31 (+3.97%), beating expectations.
Dividends
Abbott Laboratories conversion tables
 |  |
|---|---|
| 0.5 ABT | 69.99 AUD |
| 1 ABT | 139.99 AUD |
| 5 ABT | 699.98 AUD |
| 10 ABT | 1,399.96 AUD |
| |
|---|---|
| 0.5 AUD | 0.0035715 ABT |
| 1 AUD | 0.0071431 ABT |
| 5 AUD | 0.035715 ABT |
| 10 AUD | 0.071431 ABT |
More to explore
FAQ
ABT is trading at A$140.00, -0.13% over the last 24 hours. Track live moves on the price chart at the top of this page.
The ABT stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. ABT is currently trading at A$140.00, -0.13% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on ABT price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. ABT's P/E ratio is currently 31.35 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from ABT; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against ABT's historical range and other companies in the Healthcare sector.
Abbott Laboratories's market cap is currently 242.56B AUD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.